- Home
- Automated
- List of product information
- ERYCYN-250 TABLET 250 MG [SIN11952P]
ERYCYN-250 TABLET 250 MG [SIN11952P]
Active ingredients: ERYCYN-250 TABLET 250 MG
Last updated 26 October 2025
On this page
Product Info
ERYCYN-250 TABLET 250 MG
[SIN11952P]
Product information
Active Ingredient and Strength | ERYTHROMYCIN STEARATE EQV ERYTHROMYCIN - 250 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | MICRO LABS LTD - INDIA |
Registration Number | SIN11952P |
Licence Holder | NAINA MOHAMED & SONS PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J01FA01 |
INDICATIONS & USES: Upper and lower respiratory tract infections; Mycoplasma and Chlamydial infections; Skin and soft tissue infections; Diphtheria; Legionnaires disease; Otitis media; Pertussis; Chancroids.
DOSAGE AND ADMINISTRATION: 250 mg 6 hrly; the dose may be doubled for severe infections.
Gonorrhoea: 500 mg 6 hrly for 6–7 days
Syphilis: 1gm 6hrly for 10–15 days (30days in late syphilis)
Prophylaxis against streptococci: 250mg 12 hrly.
CONTRAINDICATIONS:
Erythromycin is contraindicated in patients taking astemizole, terfenadine, domperidone, cisapride or pimozide
Erythromycin should not be given to patients with a history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes (see “Warnings and Precautions” – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)
Erythromycin should not be given to patients with electrolyte disturbances (hypokalaemia, hypomagnesaemia due to the risk of prolongation of QT interval)